A Phase II Trial of STI-571/Imatinib (Gleevec (R)) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2013
At a glance
- Drugs Imatinib (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 12 Jan 2012 Actual patient number (23) added as reported by ClinicalTrials.gov.
- 12 Jan 2012 Actual end date (1 Oct 2010) added as reported by ClinicalTrials.gov.